Mark Labow, Novartis Institute, featured at Genomic & Proteomic Conference on May 30-31, Boston
Mark Labow, Executive Director, Discovery Unit: Developmental and Molecular Pathways Department, Novartis Institutes for BioMedical Research (NIBR) to give featured presentation entitled "Systematic, Genome-Scale Identification of Novel Drug Targets" at 2nd Genomic & Proteomic Drug Discovery Conference on May 30-31st in Boston, MA.
The Department of Developmental and Molecular Pathways has focus.
- (1888PressRelease) April 11, 2012 - The pharmaceutical industry faces a number of continual and growing challenges in bringing innovative new medicines to the clinic. The earliest challenge in the drug discovery process is the identification of novel, validated targets that have a high probability of providing both safe and effective therapeutic strategies. To this end, the Department of Developmental and Molecular Pathways has focused on carrying out genome-scale gain and loss of function screens in mammalian systems that model disease processes in vitro. A focus on molecular pathways associated with human disease should help ensure the clinical relevance of identified targets. Examples of target identification from genome scale gain and loss of function screens will be presented.
Benefits of this talk will be:
-Description of approaches to comprehensively define regulators of human molecular signaling pathways.
-Evaluation of the utility of large scale RNAi approaches in mammalian cells.
-Comparison of different functional genomics approaches to target discovery.
Mark Labow joined Novartis in 1998 where his group developed a platform for large-scale systematic analysis of gene function in mammalian systems. Currently, he is the Executive Director of the Discovery Unit within the Developmental Molecular Pathway (DMP) Department of the Novartis Institutes for Biomedial Research. The DMP platform integrates a number of technologies, including chemical biology and genomics, for the identification and validation of novel drug discovery strategies. The primary focus for the Discovery Unit is on building and exploiting complex in vitro and in vivo model systems for target discovery. Prior to joining Novartis, he held various positions in research at Hoffmann La-Roche from 1990 to 1998. He received his Ph.D. from the University of Florida and carried out post-doctoral work at Princeton University.
GTC's 2nd Genomic & Proteomic Drug Discovery Conference is a 2-day meeting to be held on May 30-31, at the Hyatt Harborside in Boston, MA. Additionally, there will be a supplementary Clinical Sequencing Workshop to be held on May 29th. The conference will be a forum for the use of omics based methods such as next generation sequencing and mass spectrometry for biomarker discovery and the development of novel therapeutics. Technology, diagnostics and major pharmaceuticals such as Pfizer, Roche, Novartis, GlaxoSmithKline, Merck, Sanofi, Life Technologies, Agilent and more will meet with academic and government experts to discuss the novel applications of omics based research and its implications toward personalized medicine.
For more information, please visit www.gtcbio.com